Browse studies

Find your next paid study

740 recruiting studies matching your filters

Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

The goal of this clinical trial is two-fold. First to investigate the feasibility of whether a remotely administered smartphone app can increase the volume and…

Parkinson DiseaseProdromal StageNeurodegenerative Diseases+8 more

Estimated

~$10 – $6,250

Radboud University Medical CenterNCT06993142

Clinical & Genetic Studies in ALS and Other Neurodegenerative Motor Neuron Disorders

The purpose of this study is to collect, from patients with sporadic and familial ALS and their family members, clinical data and blood samples for extraction …

Amyotrophic Lateral Sclerosis

Estimated

~$10 – $750

Mayo ClinicNCT05474235

Observational

Near-Infrared Spectroscopy-Derived Mitochondrial Oxidative Phosphorylation Capacity, Local Muscular Fatigue Resistance, and the Effects of Acute Taurine Supplementation

The goal of this clinical trial is to determine the association between near-infrared spectroscopy (NIRS)-derived mitochondrial oxidative phosphorylation (OXPH…

Local Muscular Endurance and FatigueNIRS Skeletal Muscle Mitochondrial CapacityAcute Taurine Supplementation

Estimated

~$10 – $6,250

Louisiana State University and A&M CollegeNCT07654946

Phase 3

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemothera…

Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerFallopian Tube Cancer+4 more

Estimated

~$10 – $8,750

Genelux CorporationNCT05281471

Phase 1

Master Protocol for a Phase I/II Open-label Safety and Efficacy Study of LNP.UCD.ABE, a Lipid Nanoparticle-delivered Base Editing Therapy, in Patients With Urea Cycle Disorders Due to Variants Amenable to Corrective Editing by LNP.UCD.ABE

This is a single-site Phase 1/2 open-label umbrella clinical trial designed to evaluate the safety, tolerability, and efficacy of a single intravenous dose of …

Urea Cycle DisordersCarbamoyl-Phosphate Synthase I Deficiency

Estimated

~$10 – $7,500

Rebecca Ahrens-NicklasNCT07667387

Phase 3

A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With Remibrutinib

The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuo…

Relapsing Multiple Sclerosis

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06846281

Phase 1

Consolidative Radiation Therapy or Cystectomy After Initial Favorable Response Succeeding Enfortumab Vedotin Plus Pembrolizumab (REINFORCE)--- A Pilot Feasibility Trial

This pilot feasibility clinical trial is evaluating a novel treatment strategy for patients with advanced bladder cancer that is unresectable, has spread to ne…

Muscle Invasive Bladder CarcinomaStage III Bladder Cancer AJCC v8Stage IV Bladder Cancer AJCC v8

Estimated

~$10 – $6,250

University of WashingtonNCT07579195

Phase 1

A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults With Refractory Relapsing or Progressive Multiple Sclerosis

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and toler…

Multiple Sclerosis

Estimated

~$10 – $7,500

AstraZenecaNCT07224373

Phase 3

A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with ver…

Embryonal RhabdomyosarcomaFusion-Negative Alveolar RhabdomyosarcomaSpindle Cell/Sclerosing Rhabdomyosarcoma

Estimated

~$10 – $7,500

Children's Oncology GroupNCT05304585

Phase 2

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer

TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with…

Non-muscle Invasive Bladder Cancer

Estimated

~$10 – $8,750

Protara TherapeuticsNCT05951179

Predicting Outcomes in Intermediate and High-risk Non-muscle Invasive Bladder Cancer Using Automated Analysis of Digital Pathology Data

This is a multi-center study and the aim is to develop and validate an Artificial Intelligence (AI) -based histologic analysis tool to predict responsiveness t…

Non-muscle-invasive Bladder Cancer

Estimated

~$10 – $750

University of Texas Southwestern Medical CenterNCT05825950

PREVENT ALL ALS - Longitudinal Biomarker Study for Participants Who Are Genetically at Risk for Amyotrophic Lateral Sclerosis (ALS)

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic La…

Amyotrophic Lateral Sclerosis

Estimated

~$10 – $750

St. Joseph's Hospital and Medical Center, PhoenixNCT06581861